Biopharma hiring is broken in a very specific way: we keep treating IP as a “legal function” instead of an operating system.
If you’ve ever watched a company scramble to fill roles—IP counsel, patent agents, portfolio analysts, competitive intelligence…

The Generic Cliff Isn’t a Moment—it’s a Deadline.
In pharma, “expiration” sounds like a single date on a calendar. In reality, it’s a countdown that starts years earlier—often long before anyone outside the industry can see the finish line.
A recen…

Patent thickets are the new moat—and biologics are the new battleground.
If you’ve ever wondered why some blockbuster biologic drugs seem to face fewer “clean” generic entries than you’d expect, the answer often isn’t science. It’s strategy.
A recent…

AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Most people think patent risk is something you deal with after you’ve already committed—after the acquisition, after the licensing spend, after the clinical roadmap is locked in.
Bu…

Most teams look at drug patents the wrong way.
They read claims. They track expiration dates. They wait for the next “Orange Book” update.
But in formulation patents—the ones that govern how a drug is made, stabilized, delivered, absorbed, or prote…

Russia’s VED and SSM lists aren’t just bureaucratic paperwork—they’re timing tools. And for generic manufacturers, timing is everything.
Here’s the agitation: in markets where reimbursement and procurement are tightly linked to government lists, “launc…

Pharma pipelines don’t fail because of science. They fail because of risk.
That’s the uncomfortable truth behind Freedom-to-Operate (FTO): it’s not a regulatory checkbox—it’s a business survival tool.
In an industry where a single patent can delay laun…

Beyond the ANDA: How the 505(b)(2) Pathway Can Turn “Copy” Into Competitive Moat
In generic drug land, the default strategy is often binary: file an ANDA, win on price, and hope the market does the rest. But that playbook is getting harder to sustain a…

Pharma IP teams are used to thinking in timelines: filing dates, priority claims, prosecution milestones, and—eventually—patent expiry. But in Russia, the “clock” can move in ways that are easy to miss until it’s too late.
Here’s the agitation: if your…

Drug patent portfolios are often treated like static assets—filed, granted, and then quietly shelved. But in today’s litigation-aware landscape, that mindset is increasingly expensive. The real competitive edge comes from designing your patent strategy…